(Q36575376)

15 August 2017

1 reference

title

Update on the treatment of lupus nephritis (English)

1 reference

15 August 2017

Waldman M

1

1 reference

15 August 2017

Appel GB

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

23 August 2006

1 reference

15 August 2017

1 reference

15 August 2017

70

1 reference

15 August 2017

8

1 reference

15 August 2017

1403-1412

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.ki.5001777

15 August 2017

0 references

cites work

Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

The very long-term prognosis and complications of lupus nephritis and its treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

The prognosis of lupus nephritis in African-Americans: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Mycophenolate mofetil and its mechanisms of action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Lymphocyte-Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

The safety and efficacy of MMF in lupus nephritis: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Flares in lupus nephritis: Incidence, impact on renal survival and management

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

"Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Sequential therapies for proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Balancing diversity and tolerance: lessons from patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Pathogenic autoantibodies in lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Abetimus: Abetimus sodium, LJP 394

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Rituximab and factors predictive of response in chronic immune thrombocytopenic purpura of children

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Rituximab is effective for selected patients with chronic steroid-refractory immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Treatment of humoral rejection with rituximab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Case records of the Massachusetts General Hospital. Case 31-2005. A 60-year-old man with skin lesions and renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Rituximab-induced long-term remission of membranous lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Rituximab induced remission in a patient with Wegener's granulomatosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Rituximab for idiopathic membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

An open study of B lymphocyte depletion in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Repeated B cell depletion in treatment of refractory systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Co-stimulation in T cell responses.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

CD28/B7 costimulation: a review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Co-stimulatory blockade in the treatment of murine systemic lupus erythematosus (SLE).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

T cells in the pathogenesis of systemic lupus erythematosus: potential roles of CD154-CD40 interactions and costimulatory molecules

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Aberrant Expression of the Costimulatory Molecule CD40 Ligand on Monocytes from Patients with Systemic Lupus Erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Peripheral blood lymphocytes in SLE--hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

The roles of CD28 and CD40 ligand in T cell activation and tolerance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

CD40L overexpression on T cells and monocytes from patients with systemic lupus erythematosus is resistant to calcineurin inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Early growth response-1 is required for CD154 transcription

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

CTLA-4 ligation blocks CD28-dependent T cell activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

CTLA-4 is a second receptor for the B cell activation antigen B7

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

The interaction properties of costimulatory molecules revisited.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Re-establishing peripheral tolerance in the absence of CTLA-4: complementation by wild-type T cells points to an indirect role for CTLA-4

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Treatment of murine lupus with CTLA4Ig

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Costimulation blockade with belatacept in renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Interferon-alpha: a new target for therapy in systemic lupus erythematosus?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

The emerging role of interferon in human systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

CpG motifs in bacterial DNA and their immune effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

G-rich DNA suppresses systemic lupus.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Membranous lupus nephropathy: a clinicopathologic study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

The classification of glomerulonephritis in systemic lupus erythematosus revisited

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

The classification of glomerulonephritis in systemic lupus erythematosus revisited

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Treatment of membranous lupus nephritis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Lupus nephritis: treatment with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Mycophenolate therapy of SLE membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Premature atherosclerosis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001777

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5001777

1 reference

release_kzp6bdpaxzbqdn3gwcdvt5s5au

15 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kzp6bdpaxzbqdn3gwcdvt5s5au

24 November 2022

mapped directly with Wikidata item

1 reference